Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in Chinese Participants With Active Non-radiographic Axial Spondyloarthritis
NCT04732117Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2021
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of secukinumab in non-radiographic axial spondyloarthritis (nr-axSpA), sponsored by Novartis. Started Jul 2021; status: completed.
02
Drugs
secukinumab
03
Conditions
non-radiographic axial spondyloarthritis (nr-axSpA)
Beyond the preview
Go deeper on NCT04732117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04732117.